Literature DB >> 9145629

Primary care paradigm for management of sarcoidosis, Part 2.

R C Young1, R E Rachal, B Nelson-Knuckles, C N Arthur, H V Nevels.   

Abstract

Sarcoidosis is a systemic granulomatous disease of undetermined etiology in which the immune system is overstimulated. Management of the patient with sarcoidosis entails continuity of patient care far beyond disease, even into remission. Care is comprehensive, including all involved organ systems, coordination of specialty consultations and services, and includes diagnostic tests. Therapeutic decisions are the responsibility of the primary care practitioner. Prognosis of sarcoidosis is not uniformly good. Patients can die. Subacute sarcoidosis patients usually do not require pharmacologic therapy. Chronic sarcoidosis may require long-term treatment for years to indefinitely. Corticosteroids are still the drugs of choice and other therapy is now available. Health organizations and private nonprofit support groups are available for patient education and assistance. Close support must still come from the family unit. Sarcoidosis may occur in family members in different cohorts at all ages in life and in any racial or ethnic group. The second in a two-part series on management of the patient with sarcoidosis, this article describes coordination of care and considers community, prevention, and family aspects of the disease.

Entities:  

Mesh:

Year:  1997        PMID: 9145629      PMCID: PMC2608215     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  66 in total

1.  The preparation and standardization of Kveim testing antigen.

Authors:  M W CHASE
Journal:  Am Rev Respir Dis       Date:  1961-11

2.  Sarcoidosis; report of three cases in siblings under fifteen years of age.

Authors:  E L KENDIG; R L PEACOCK; S RYBURN
Journal:  N Engl J Med       Date:  1959-05-07       Impact factor: 91.245

3.  Sarcoidosis among children. A review.

Authors:  E L KENDIG
Journal:  J Pediatr       Date:  1962-08       Impact factor: 4.406

4.  Pulmonary function in sarcoidosis; results with cortisone therapy.

Authors:  D J STONE; A SCHWARTZ; J A FELTMAN; F J LOVELOCK
Journal:  Am J Med       Date:  1953-10       Impact factor: 4.965

5.  Pulmonary function studies in sarcoidosis.

Authors:  E O COATES; J H COMROE
Journal:  J Clin Invest       Date:  1951-08       Impact factor: 14.808

6.  The Kveim test after Siltzbach.

Authors:  A S Teirstein
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

7.  Oxygen cost of breathing. II. Studies in patients with sarcoidosis.

Authors:  K A Harden; R C Young; C Carr; J R Laurey
Journal:  Am Rev Respir Dis       Date:  1968-06

8.  Sarcoidosis in Washington, D. C. Clinical observations in 105 black patients.

Authors:  R C Young; P Y Titus-Dillon; M L Schneider; T G Shelton; R L Hackney; K A Harden
Journal:  Arch Intern Med       Date:  1970-01

9.  Childhood sarcoidosis.

Authors:  E N Pattishall; G L Strope; S M Spinola; F W Denny
Journal:  J Pediatr       Date:  1986-02       Impact factor: 4.406

10.  Chromosomal aneuploidy in sarcoid granuloma cells.

Authors:  T Okabe; A Suzuki; H Ishikawa; I Watanabe; F Takaku
Journal:  Am Rev Respir Dis       Date:  1986-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.